August 2017

NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Clinical Study Agreement (CSA) with the University of British Columbia in Canada to begin a clinical trial with its CanChew Plus® cannabidiol (CBD) chewing gum […]

by

NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Clinical Study Agreement (CSA) with the University of British Columbia in Canada to begin a clinical trial with its CanChew Plus® cannabidiol (CBD) chewing gum […]

by

What CBDs (Cannabidiols) Are Currently In Clinical Trials And What Results Are They Proving As CBD (cannabidiol) comes into the light of the public eye, the curiosity of government researchers continues to grow. Through this growth of interest comes with it funding for real science and research into the mysteries of cannabis sativa and specifically, […]

by

Biopharmaceutical company, GW Pharmaceuticals announced that the European Medicines Agency (EMA) has granted orphan drug designation to GW’s investigational product Epidiolex (cannabidiol [CBD]) in the treatment of Lennox-Gastaut Syndrome (LGS), a treatment-resistant, debilitating childhood-onset epilepsy. “Following two positive Phase III trials of Epidiolex in patients with LGS, GW is committed to pursuing registration of Epidiolex in Europe […]

by

What CBDs (Cannabidiols) Are Currently In Clinical Trials And What Results Are They Proving As CBD (cannabidiol) comes into the light of the public eye, the curiosity of government researchers continues to grow. Through this growth of interest comes with it funding for real science and research into the mysteries of cannabis sativa and specifically, […]

by

– Epidiolex® NDA submission process underway – – Conference call today at 4:30 p.m. EDT – LONDON and CARLSBAD, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results […]

by

While a growing number of states have legalized marijuana for medical use, medical marijuana differs from pharmaceutical treatments in that even legal forms are not FDA regulated. For this reason MMJ BioScience will follow the FDA’s strict regulatory development process for MMJ BioScience’s first pharmaceutical cannabidiol (CBD) derived medicine. Buffalo, New York (PRWEB) August 27, […]

by

A new world of cannabis breeding is now at your fingertips in the form of technology. Traditionally, one’s fingertips helped to guide a breeding program, to some degree, in that growers and breeders utilized the tip of thumb and forefinger to rub the stems of the vegetating plant for superior odor, combined with vigor and […]

by

According to a recent report by New Frontier Data, the Viridian Cannabis Stock Index gained 236.1% in 2016 and outperforming such mainstream indexes as the Russell 2000 (up 19.5%), the Dow Jones Industrial Average (up 13.4%), the SP 500 (up 9.5%), and the Nasdaq composite (up 7.5%). By examining the underlying sectors in the cannabis […]

by

August 24, 2017 (Investorideas.com Newswire) Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks releases a snapshot of companies in the cannabis/marijuana sector that are developing methods for cannabinoids to be used as medicine and treatments for cancer, epilepsy, concussions and traumatic brain injury. The Hemp Business Journal projects that the […]

by

Dive Brief: OWC Pharmaceutical Research, which develops cannabinoid-based therapies, has inked a deal with Medmar, giving it access to a no-interest loan of $300,000 available in six installments between September 2016 and February 2017. The Israeli-based company has earmarked the money for development of its cannabinoid-based psoriasis cream, which it is working on in collaboration […]

by

SECFilings.com reported the publication of an article showcasing Axim Biotechnologies Inc (OTCMKTS:AXIM) clinical progress and portfolio in light of Zynerba’s Phase II Cannabidiol gel patch failure. The clinical trial of 188 subjects with refractory epilepsy showed that those administered a low dose of ZYN002 recorded an 18.4% median drop in seizures versus a 14% drop […]

by

HB130 would let researchers who conduct institutional review board-approved studies possess and administer cannabinoid products to study participants, as well as import cannabis and related products from other states for study use— as long as the materials comply with federal law and are obtained from the National Institute on Drug Abuse. In January, Utah lawmakers […]

by